The U.S. Food and Drug Administration (FDA) has approved 56 biosimilars as of the first half of this year. Twelve of these were from Korean companies, ranking second after the United States.

Until now, companies from the United States, South Korea, Germany, and Swiss dominated the U.S. biosimilar market. Recently, companies from India, Iceland, and China have joined the market.

On July 2nd, the Korea Biotechnology Industry Organization posted an issue briefing and reported the current U.S. biosimilar approvals. According to the document, 56 biosimilar products received the U.S. FDA approvals as of the first half of this year.

By country, the United States companies had the